Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover.
In hypertensive heart disease, after myocardial infarction or in congestive heart failure, myocardial fibrosis presenting as a diffuse perivascular and interstitial accumulation of fibrillar collagens within the normal connective tissue structures of the myocardium is associated with an activated renin-angiotensin system (RAS). This reactive fibrosis occurs in the overloaded left ventricle and the nonoverloaded right ventricle irrespective of myocyte necrosis or the development of myocyte hypertrophy. Therefore, it appears that hemodynamic factors or the load of the ventricle are not primarily responsible for the adverse fibrous tissue response in the myocardium, and humoral factors may play a key role in regulating the myocardial collagen matrix. The neurohumoral response in hypertensive heart disease, after myocardial infarction with overall deterioration of left ventricular function or congestive heart failure leads to an activation of either the cardiac or the circulating RAS, which closely interacts with the bradykinin-prostaglandin system. To ascertain whether the RAS modulates collagen fibroblasts that express mRNAs for types I and III collagens (the major fibrillar collagens in the heart) and matrix metalloproteinase 1 (MMP1; the key enzyme for collagen degradation), collagen synthesis was measured by [3H]proline incorporation normalized to total protein synthesis and MMP1 activity was determined by degradation of [14C]collagen in cultured fibroblasts after 24-hour incubation with various concentrations of angiotensin II or PGE2 (10(-11)-10(-3) M) under serum-free conditions. In addition, effects of angiotensin II were evaluated in the presence or absence of either type 1 (ICI D8731) or type 2 (PD 123177) angiotensin II (AT1 or PGE2 (10(-11)-10(-3) M) under serum-free conditions.(ABSTRACT TRUNCATED AT 250 WORDS)
D000328:Adult; D000804:Angiotensin II / Q000502:physiology*; D057911:Angiotensin Receptor Antagonists; D000917:Antibody Formation / Q000502:physiology; D003094:Collagen / Q000276:immunology / Q000378:metabolism*; D017364:Collagenases / Q000378:metabolism; D003238:Connective Tissue / Q000378:metabolism; D015232:Dinoprostone / Q000502:physiology*; D004719:Endomyocardial Fibrosis / Q000378:metabolism; D005347:Fibroblasts / Q000378:metabolism*; D006333:Heart Failure / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000378:metabolism; D020781:Matrix Metalloproteinase 1; D009203:Myocardial Infarction / Q000378:metabolism; D009206:Myocardium / Q000276:immunology / Q000378:metabolism*; D018377:Neurotransmitter Agents / Q000502:physiology; D012084:Renin-Angiotensin System / Q000502:physiology; D018487:Ventricular Dysfunction, Left / Q000378:metabolism
D057911:Angiotensin Receptor Antagonists; D018377:Neurotransmitter Agents; D000804:Angiotensin II; D003094:Collagen; D017364:Collagenases; D020781:Matrix Metalloproteinase 1; D015232:Dinoprostone